Research programme: Parkinson's disease therapeutics - Alnylam Pharmaceuticals/Mayo Clinic

Drug Profile

Research programme: Parkinson's disease therapeutics - Alnylam Pharmaceuticals/Mayo Clinic

Latest Information Update: 13 Nov 2008

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Mayo Clinic
  • Class Small interfering RNA
  • Mechanism of Action Alpha-synuclein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 05 Nov 2008 Interim pharmacodynamics and safety data from a preclinical trial in a mouse model of Parkinson's disease released by Alnylam Pharmaceuticals
  • 05 Jan 2008 Alnylam Pharmaceuticals, the Mayo Clinic, and the Parkinson's Institute and Clinical Center receive a grant from the Michael J. Fox Foundation for development of therapeutics targeting alpha-synuclein for Parkinson's disease
  • 10 Dec 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top